| __timestamp | Ionis Pharmaceuticals, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 7461000 |
| Thursday, January 1, 2015 | 37173000 | 11960000 |
| Friday, January 1, 2016 | 48616000 | 13108000 |
| Sunday, January 1, 2017 | 108488000 | 17501000 |
| Monday, January 1, 2018 | 244622000 | 22472000 |
| Tuesday, January 1, 2019 | 287000000 | 24286000 |
| Wednesday, January 1, 2020 | 354000000 | 29689000 |
| Friday, January 1, 2021 | 186000000 | 38837000 |
| Saturday, January 1, 2022 | 151000000 | 47489000 |
| Sunday, January 1, 2023 | 232600000 | 53379000 |
| Monday, January 1, 2024 | 267474000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Ionis Pharmaceuticals, Inc. and Xencor, Inc. from 2014 to 2023. Over this period, Ionis Pharmaceuticals has consistently outpaced Xencor in SG&A spending, reflecting its larger scale and broader operational scope. In 2020, Ionis reached its peak, spending nearly 13 times more than Xencor. However, by 2023, Ionis reduced its expenses by 34% from its 2020 high, while Xencor's costs grew steadily, increasing by 615% since 2014. This divergence highlights Ionis's strategic cost management and Xencor's growth trajectory. Understanding these trends provides valuable insights into each company's operational strategies and market positioning, offering a glimpse into their future potential in the biotech industry.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Comparing SG&A Expenses: AstraZeneca PLC vs Ionis Pharmaceuticals, Inc. Trends and Insights
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Xencor, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Xencor, Inc.